Artboard 33Artboard 16Artboard 18Artboard 13Artboard 42Artboard 21Artboard 4Artboard 5Artboard 45Artboard 22Artboard 7Artboard 42Artboard 23Artboard 17?Artboard 28Artboard 43Artboard 49Artboard 47Artboard 15Artboard 32Artboard 6Artboard 22Artboard 5Artboard 25Artboard 1Artboard 42Artboard 11Artboard 41Artboard 11Artboard 23Artboard 10Artboard 4Artboard 9Artboard 6Artboard 8Artboard 7Artboard 3Artboard 12Artboard 25Artboard 34Artboard 43Artboard 44Artboard 16Artboard 24Artboard 13Artboard 5Artboard 24Artboard 31Artboard 1Artboard 12Artboard 27Artboard 30Artboard 36Artboard 44Artboard 9Artboard 17Artboard 6Artboard 27Artboard 30Artboard 29Artboard 26Artboard 2Artboard 20Artboard 35Artboard 15Artboard 14Artboard 50Artboard 26Artboard 14Artboard 40Artboard 21Artboard 10Artboard 37Artboard 46Artboard 33Artboard 8

Wiley Series On Technologies For The Pharmaceutical Industry (Cód: 9396724)


John Wiley & Sons

Ooops! Este produto não está mais a venda.
Mas não se preocupe, temos uma versão atualizada para você.

Ooopss! Este produto está fora de linha, mas temos outras opções para você.
Veja nossas sugestões abaixo!

R$ 783,40

em até 10x de R$ 78,34 sem juros
Cartão Saraiva: 1x de R$ 744,23 (-5%)


Em até 1x sem juros de

Cartão Saraiva:


Em até 10x sem juros de

Wiley Series On Technologies For The Pharmaceutical Industry


Quer comprar em uma loja física? Veja a disponibilidade deste produto

Entregas internacionais: Consulte prazos e valores de entrega para regiões fora do Brasil na página do Carrinho.

ou receba na loja com frete grátis

Formas de envio Custo Entrega estimada

* Válido para compras efetuadas em dias úteis até às 15:00, horário de Brasília, com cartão de crédito e aprovadas na primeira tentativa.

X Consulte as lojas participantes

Saraiva MegaStore Shopping Eldorado Av. Rebouças, 3970 - 1º piso - Pinheiros CEP: 05402-600 - São Paulo - SP


Can academia save the pharmaceutical industry? The pharmaceutical industry is at a crossroads. The urgent need for novel therapies cannot stem the skyrocketing costs and plummeting productivity plaguing R&D, and many key products are facing patent expiration. Dr. Rathnam Chaguturu presents a case for collaboration between the pharmaceutical industry and academia that could reverse the industry's decline. Collaborative Innovation in Drug Discovery: Strategies for Public and Private Partnerships provides insight into the potential synergy of basing R&D in academia while leaving drug companies to turn hits into marketable products. As Founder and CEO of iDDPartners, focused on pharmaceutical innovation, Founding president of the International Chemical Biology Society, and Senior Director-Discovery Sciences, SRI International, Dr. Chaguturu has assembled a panel of experts from around the world to weigh in on issues that affect the two driving forces in medical advancement. Gain global perspectives on the benefits and potential issues surrounding collaborative innovation Discover how industries can come together to prevent another 'Pharma Cliff' Learn how nonprofits are becoming the driving force behind innovation Read case studies of specific academia-pharma partnerships for real-life examples of successful collaboration Explore government initiatives that help foster cooperation between industry and academia Dr. Chaguturu's thirty-five years of experience in academia and industry, managing new lead discovery projects and forging collaborative partnerships with academia, disease foundations, nonprofits, and government agencies lend him an informative perspective into the issues facing pharmaceutical progress. In Collaborative Innovation in Drug Discovery: Strategies for Public and Private Partnerships, he and his expert team provide insight into the various nuances of the debate. Sets the stage for a new, improved paradigm in drug discovery Despite spending more than $135 billion annually on R&D, the pharmaceutical industry faces an innovation crisis. Given the complexities and the expense of R&D, this book argues that we can accomplish much more--with greater efficiency and less cost--when private and public sectors collaborate, each focusing on their core strengths. Collaborative Innovation in Drug Discovery focuses on the early stage of drug discovery, the most critical barrier to delivering a steady flow of viable drug candidates into the pipeline. The book assesses the current state of drug discovery in the pharmaceutical industry, government, non-profit, and academia, identifying the areas where each sector excels and areas where gaps exist. Next, the authors explore ways these sectors can establish mutually beneficial partnerships in order to discover, develop, and bring to market improved, safer drugs to treat human diseases. Topics include: Status of healthcare and unmet medical needs Biomedical research environment, drug discovery efforts, and market risks in industry and academia NIH Roadmap and EU-OpenScreen initiatives Trends in academia-pharmaceutical partnerships, including case studies Drug repositioning, open source partnerships, and challenges and practices for conducting clinical trials Editor Rathnam Chaguturu has assembled a panel of expert authors from around the world, representing all the sectors involved in drug discovery. Their contributions are not only based on a thorough review of the current literature, but also their own first-hand experience of what works and what doesn't. Collaborative Innovation in Drug Discovery offers pharmaceutical scientists and managers working in both private and public sectors a new, more productive road map to discover drugs that the world needs. Foreword by Murad, Ferid


Peso 1.16 Kg
Produto sob encomenda Sim
Marca John Wiley & Sons
I.S.B.N. 9780470917374
Referência 025508756
Altura 23.62 cm
Largura 15.75 cm
Profundidade 3.81 cm
Idioma Inglês
Acabamento Capa dura
Cód. Barras 9780470917374
Ano da edição 2014